Showing 141 - 160 results of 193 for search '"cancer immunotherapy"', query time: 0.06s Refine Results
  1. 141

    Innovative applications and future trends of multiparametric PET in the assessment of immunotherapy efficacy by Tingting Qiao, Tingting Qiao, Zhaoping Cheng, Yanhua Duan

    Published 2025-01-01
    “…Future validation using large-scale, multicenter datasets is needed to further advance precision medicine in cancer immunotherapy.…”
    Get full text
    Article
  2. 142
  3. 143

    Comprehensive single-cell pan-cancer atlas unveils IFI30+ macrophages as key modulators of intra-tumoral immune dynamics by Lihe Jiang, Lihe Jiang, Lihe Jiang, Peili Wang, Peili Wang, Yixuan Hou, Jingying Chen, Hua Li, Hua Li

    Published 2025-01-01
    “…Despite its recognition in cancer immunotherapy, IFI30 remains a nascent focus. Our approach involves a multi-omics analysis of IFI30 tumor immunological profile in the macrophage-mediated Tumor Microenvironment (TME), spanning various cancers and bolstered by rigorous co-culture laboratory work.ResultsIFI30 predominantly localizes in monocyte/macrophage populations, correlating strongly with immune cell infiltration. …”
    Get full text
    Article
  4. 144

    Activatable Sulfur Dioxide Nanosonosensitizer Enables Precisely Controllable Sono‐Gaseous Checkpoint Trimodal Therapy for Orthotopic Hepatocellular Carcinoma by Jing Liang, Guangwen Cheng, Luping Qiu, Liyun Xue, Huning Xu, Xiaohui Qiao, Na Guo, Huijing Xiang, Yu Chen, Hong Ding

    Published 2025-02-01
    “…Precisely controllable strategies combining sulfur dioxide (SO2) gas therapy with cancer immunotherapy can address these issues but remain lacking. …”
    Get full text
    Article
  5. 145

    CD155 promotes the progression of colorectal cancer by restraining CD8+ T cells via the PI3K/AKT/NF-κB pathway by Rongpu Liang, Liting Liu, Dongbing Ding, Yiquan Li, Jiannan Ren, Bo Wei

    Published 2025-02-01
    “…CD155 may become an important prognostic biomarker and an effective target for colorectal cancer immunotherapy.…”
    Get full text
    Article
  6. 146

    Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Mela... by Mengqi Zhang, Lulu Wang, Wan Liu, Tian Wang, Francesco De Sanctis, Lifang Zhu, Guizhong Zhang, Jian Cheng, Qin Cao, Jingying Zhou, Aldo Tagliabue, Vincenzo Bronte, Dehong Yan, Xianchun Wan, Guang Yu

    Published 2022-01-01
    “…These findings indicate that ART controls the functional polarization of MDSCs and targeting MDSCs by ART provides a novel therapeutic strategy to enhance anti-PD-L1 cancer immunotherapy.…”
    Get full text
    Article
  7. 147

    Akkermansia muciniphila Enhances the Antitumor Effect of Cisplatin in Lewis Lung Cancer Mice by Zhuo Chen, Xiang Qian, Shasha Chen, Xiaoxuan Fu, Guanjun Ma, Aiqin Zhang

    Published 2020-01-01
    “…Recently, intestinal flora plays a vital role in the occurrence and development of tumors and there is link between cancer immunotherapy and Akkermansia muciniphila (Akk). However, the therapeutic efficacy of Akk in lung cancer remained unclear. …”
    Get full text
    Article
  8. 148

    Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity by Nilberto Dias de Araújo, Fábio Magalhães Gama, Mateus de Souza Barros, Thaís Lohana Pereira Ribeiro, Fabíola Silva Alves, Lilyane Amorim Xabregas, Andréa Monteiro Tarragô, Adriana Malheiro, Allyson Guimarães Costa

    Published 2021-01-01
    “…Collectively, these T cell populations can recognize lipid antigens, specially modified peptides and small molecule metabolites, in addition to having several other advantages, which can provide more effective applications in cancer immunotherapy. In recent years, these cell populations have been associated with a repertoire of anti- or protumor responses and play important roles in the dynamics of solid tumors and hematological malignancies, thus, encouraging the development of new investigations in the area. …”
    Get full text
    Article
  9. 149
  10. 150

    Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma by Mayuna Nakamura, Yuka Tanaka, Keishi Hakoda, Masahiro Ohira, Tsuyoshi Kobayashi, Kenji Kurachi, Kouichi Tamura, Hideki Ohdan

    Published 2025-02-01
    “…Recently, cell-based immunotherapy using natural killer (NK) cells has attracted considerable attention in cancer immunotherapy. NK cells generated from induced pluripotent stem cells (iPSCs) are a new option for use as an NK cell resource. …”
    Get full text
    Article
  11. 151

    Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy by Jiayuan Le, Yuming Sun, Guangtong Deng, Yating Dian, Yanli Xie, Furong Zeng

    Published 2025-12-01
    “…The utilization of immune-checkpoint inhibitors (ICIs) in cancer immunotherapy frequently leads to the occurrence of immune-related adverse events (irAEs), making it generally not recommended for patients with preexisting autoimmune diseases. …”
    Get full text
    Article
  12. 152
  13. 153

    Neo-BCV: A Novel Bacterial Liquid Complex Vaccine for Enhancing Dendritic Cell-Mediated Immune Responses Against Lung Cancer by Zilong Zhu, Zhuze Chu, Fei Fei, Chenxi Wu, Zhengyue Fei, Yuxia Sun, Yun Chen, Peihua Lu

    Published 2025-01-01
    “…Conclusions: These findings highlight Neo-BCV’s potential as a safe and effective therapeutic strategy, offering a novel avenue for clinical translation in lung cancer immunotherapy.…”
    Get full text
    Article
  14. 154

    Identification of signaling networks associated with lactate modulation of macrophages and dendritic cells by Rapeepat Sangsuwan, Bhasirie Thuamsang, Noah Pacifici, Phum Tachachartvanich, Devan Murphy, Abhineet Ram, John Albeck, Jamal S. Lewis

    Published 2025-02-01
    “…The advancement in the understanding of cancer immune evasion has manifested the development of cancer immunotherapeutic approaches such as checkpoint inhibitors and interleukin agonists. Although cancer immunotherapy breakthroughs have demonstrated improved potency for cancer treatment, only a fraction of patients effectively respond to these treatments. …”
    Get full text
    Article
  15. 155

    A high-valence bismuth(V) nanoplatform triggers cancer cell death and anti-tumor immune responses with exogenous excitation-free endogenous H2O2- and O2-independent ROS generation by Yizhang Tang, Xujiang Yu, Liangrui He, Meng Tang, Wenji Yue, Ruitong Chen, Jie Zhao, Qi Pan, Wanwan Li

    Published 2025-01-01
    “…Overall, this work offers a nanomedicine based on high-valence bismuth(V) nanoplatform and underscores its great potential for cancer immunotherapy.…”
    Get full text
    Article
  16. 156

    PLGA confers upon conventional nonfluorescent molecules luminescent properties to trigger 1O2-induced pyroptosis and immune response in tumors by Lan Zou, Rujing Wang, Mengnan Zhao, Yuke Li, Chen Sun, Jinjin Xie, Yan Chen, Qian Jing, Dandan Mi, Sanjun Shi

    Published 2025-01-01
    “…Abstract Pyroptosis, a recently identified cellular demise regulated by gasdermin family proteins, is emerging as a promising avenue in cancer immunotherapy. However, the realm of light-controlled pyroptosis in cancer cells remains largely unexplored. …”
    Get full text
    Article
  17. 157

    Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites by Yun Teng, Chao Luo, Xiaolan Qiu, Jingyao Mu, Mukesh K. Sriwastva, Qingbo Xu, Minmin Liu, Xin Hu, Fangyi Xu, Lifeng Zhang, Juw Won Park, Jae Yeon Hwang, Maiying Kong, Zhanxu Liu, Xiang Zhang, Raobo Xu, Jun Yan, Michael L. Merchant, Craig J. McClain, Huang-Ge Zhang

    Published 2025-02-01
    “…Here we investigate the impact of plant-derived nanoparticles (PNP) on gut microbiota and metabolites in context of cancer immunotherapy with the humanized gnotobiotic mouse model. …”
    Get full text
    Article
  18. 158
  19. 159

    CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma by Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, David Mikolon, Massimo Ammirante, Sharmistha Acharya, Jon Lloyd, Mahan Abbasian, Rama Krishna Narla, Joseph R. Piccotti, Katie Stamp, Ho Cho, Kandasamy Hariharan

    Published 2024-12-01
    “…The CD47-SIRPα axis has become an important target for cancer immunotherapy. To date, the advancement of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hematologic toxicity including anemia. …”
    Get full text
    Article
  20. 160

    Pan-cancer characterization of m6A-mediated regulation of T cell exhaustion dynamics and clinical relevancies in human cancers by Weiping Ji, Ye Fang, Liwei Chen, Yitong Zheng, Yifei Pei, Changqiu Mei, Meng Zhou

    Published 2025-03-01
    “…Our findings provide novel insights into the role of m6A in TEX regulation and underscore the potential of m6A regulators as biomarkers and therapeutic targets for advancing cancer immunotherapy.…”
    Get full text
    Article